-+ 0.00%
-+ 0.00%
-+ 0.00%
Nxera Pharma Seeks South Korean Approval for Vamorolone to Treat DMD
Share
Listen to the news
Nxera Pharma Seeks South Korean Approval for Vamorolone to Treat DMD
  • Nxera Pharma submitted a marketing authorization application in South Korea for vamorolone to treat Duchenne muscular dystrophy.
  • Regulatory approval is targeted for 2027, with commercial launch planned for 2028.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nxera Pharma Co. Ltd. published the original content used to generate this news brief on October 22, 2026, and is solely responsible for the information contained therein.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending